American Century Companies Inc. Has $291,000 Position in SpringWorks Therapeutics, Inc. (NASDAQ:SWTX)

American Century Companies Inc. reduced its stake in shares of SpringWorks Therapeutics, Inc. (NASDAQ:SWTX) by 20.8% in the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 7,733 shares of the company’s stock after selling 2,032 shares during the quarter. American Century Companies Inc.’s holdings in SpringWorks Therapeutics were worth $291,000 as of its most recent SEC filing.

Other hedge funds have also recently bought and sold shares of the company. SG Americas Securities LLC grew its holdings in shares of SpringWorks Therapeutics by 8.3% during the first quarter. SG Americas Securities LLC now owns 4,673 shares of the company’s stock worth $230,000 after purchasing an additional 358 shares during the last quarter. First Horizon Advisors Inc. grew its holdings in shares of SpringWorks Therapeutics by 47.9% during the second quarter. First Horizon Advisors Inc. now owns 1,183 shares of the company’s stock worth $45,000 after purchasing an additional 383 shares during the last quarter. American International Group Inc. grew its holdings in shares of SpringWorks Therapeutics by 1.2% during the first quarter. American International Group Inc. now owns 33,751 shares of the company’s stock worth $1,661,000 after purchasing an additional 394 shares during the last quarter. CANADA LIFE ASSURANCE Co grew its holdings in shares of SpringWorks Therapeutics by 20.3% during the first quarter. CANADA LIFE ASSURANCE Co now owns 4,465 shares of the company’s stock worth $220,000 after purchasing an additional 754 shares during the last quarter. Finally, Principal Financial Group Inc. grew its holdings in shares of SpringWorks Therapeutics by 5.1% during the first quarter. Principal Financial Group Inc. now owns 16,944 shares of the company’s stock worth $834,000 after purchasing an additional 824 shares during the last quarter.

Analysts Set New Price Targets

Several research firms recently issued reports on SWTX. Wedbush reiterated an “outperform” rating and issued a $77.00 price target (up previously from $75.00) on shares of SpringWorks Therapeutics in a report on Wednesday, August 28th. HC Wainwright reiterated a “buy” rating and issued a $76.00 price target on shares of SpringWorks Therapeutics in a report on Wednesday, August 28th. Finally, JPMorgan Chase & Co. raised their price target on SpringWorks Therapeutics from $64.00 to $68.00 and gave the company an “overweight” rating in a report on Wednesday, September 4th. Six equities research analysts have rated the stock with a buy rating, According to MarketBeat, SpringWorks Therapeutics presently has an average rating of “Buy” and an average price target of $68.50.

SpringWorks Therapeutics Price Performance

NASDAQ SWTX opened at $32.64 on Friday. The firm has a market cap of $2.42 billion, a P/E ratio of -6.35 and a beta of 0.79. The stock’s 50-day moving average is $36.62 and its 200-day moving average is $40.13. SpringWorks Therapeutics, Inc. has a one year low of $18.00 and a one year high of $53.92.

SpringWorks Therapeutics (NASDAQ:SWTX) last released its quarterly earnings results on Wednesday, August 7th. The company reported ($0.54) EPS for the quarter, topping analysts’ consensus estimates of ($1.12) by $0.58. The business had revenue of $59.73 million for the quarter, compared to analyst estimates of $34.42 million. The company’s revenue for the quarter was up 59732900.0% compared to the same quarter last year. During the same period in the prior year, the business earned ($1.25) EPS. Equities analysts anticipate that SpringWorks Therapeutics, Inc. will post -3.36 EPS for the current year.

SpringWorks Therapeutics Company Profile

SpringWorks Therapeutics, Inc, a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for underserved patient populations suffering from rare diseases and cancer. Its lead product candidate is OGSIVEO (nirogacestat), an oral small molecule gamma secretase inhibitor that is in Phase III DeFi trial for the treatment of desmoid tumors; and Nirogacestat, is also in Phase 2 clinical development as a monotherapy for the treatment of ovarian granulosa cell tumors (GCT), a subtype of ovarian cancer.